12:00 AM
 | 
Oct 01, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Seebri Breezhaler regulatory update

Japan's Ministry of Health, Labor and Welfare (MHLW) approved Seebri glycopyrronium bromide Inhalation Capsules (NVA237) from Novartis as a once-daily inhaled maintenance bronchodilator treatment for chronic obstructive pulmonary disease (COPD). The product will...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >